DMD Large equally mixed donor pool

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on July 26, 2007; DOI: 10.1124/dmd.107.016048


This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
dmd.107.016048v1
35/10/1926    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Aimova, D.
Right arrow Articles by Stiborova, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aimova, D.
Right arrow Articles by Stiborova, M.


Received for publication April 3, 2007.
Revised July 21, 2007.
Accepted for publication July 23, 2007.

The anticancer drug ellipticine is a potent inducer of rat cytochromes P450 1A1 and -1A2, thereby modulating its own metabolism

Dagmar Aimova 1, Lucie Svobodova 1, Vera Kotrbova 1, Barbora Mrazova 1, Petr Hodek 1, Jiri Hudecek 1, Radka Vaclavikova 2, Eva Frei 3, Marie Stiborova 4*

1 Charles University in Prague 2 Center of Occupational Diseases 3 German Cancer Research Center 4 Charles University, Faculty of Science

* Address correspondence to: E-mail: stiborov{at}natur.cuni.cz

Abstract

Ellipticine is an antineoplastic agent, whose mode of action is based mainly on DNA intercalation, inhibition of topoisomerase II and formation of covalent DNA adducts mediated by cytochromes P450 (CYP) and peroxidases. Here, this drug was found to induce CYP1A1 and/or 1A2 enzymes and their enzymatic activities in livers, lungs and kidneys of rats treated (i.p.) with ellipticine. The induction is transient. In the absence of repeated administration of ellipticine, the levels and activities of the induced CYP1A decreased almost to the basal level two weeks after treatment. The ellipticine-mediated CYP1A induction increases the DNA adduct formation by the compound. When microsomal fractions from livers, kidneys and lungs of rats treated with ellipticine were incubated with ellipticine, DNA adduct formation, measured by 32P-postlabelling analysis, was up to 3.8-fold higher in incubations with microsomes from pretreated rats than with controls. The observed stimulation of DNA adduct formation by ellipticine was attributed to induction of CYP1A1 and/or 1A2-mediated increase in ellipticine oxidative activation to 13-hydroxy- and 12-hydroxyellipticine, the metabolites generating two major DNA adducts in human and rat livers. In addition to these metabolites, increased formation of the excretion products 9-hydroxy- and 7-hydroxyellipticine was also observed in microsomes of rats treated with ellipticine. Taken together, these results demonstrate for the first time that by inducing CYP1A1/2, ellipticine increases its own metabolism leading both to an activation of this drug to reactive species forming DNA adducts and to detoxication metabolites, thereby modulating to some extent its pharmacological and/or genotoxic potential.


Key words: CYP induction, CYP1A, cytochrome P450, DNA adducts





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics.